Corbus Pharmaceuticals Holdings (CRBP) Enterprise Value (2013 - 2025)

Corbus Pharmaceuticals Holdings' Enterprise Value history runs 13 years deep, the most recent figure standing at -$27.8 million for Q4 2025.

• On a quarterly basis, Enterprise Value fell 123.63% year-over-year to -$27.8 million in Q4 2025; TTM through Dec 2025 was -$27.8 million, a 123.63% decrease from a year earlier, with the FY2025 full-year figure at -$27.8 million, down 123.63% from the prior year.
• Enterprise Value slipped to -$27.8 million in Q4 2025 per CRBP's latest filing, from -$25.8 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$3.1 million in Q1 2023 and bottomed at -$159.4 million in Q3 2024.
• The 5-year median for Enterprise Value is -$46.8 million (2022), against an average of -$60.5 million.
• Across the five-year window, Enterprise Value tumbled 7742.96% in 2021 and jumped 92.65% in 2023, its largest moves.
• Year by year, Enterprise Value stood at -$25.2 million in 2021, then tumbled by 134.92% to -$59.2 million in 2022, then jumped by 64.68% to -$20.9 million in 2023, then soared by 40.51% to -$12.4 million in 2024, then plunged by 123.63% to -$27.8 million in 2025.
• Per Business Quant, the three latest CRBP Enterprise Value figures stand at -$27.8 million (Q4 2025), -$25.8 million (Q3 2025), and -$116.6 million (Q2 2025).